340B and IRA MFP non-duplication workflow for manufacturer teams

The Inflation Reduction Act (IRA) of 2022 authorizes Medicare to negotiate a Maximum Fair Price (MFP) for certain high-cost single-source drugs. The first 10 negotiated Part D drugs have MFPs effective January 1, 2026. For every negotiated drug that is also subject to 340B pricing, the statute requires manufacturers to provide the lower of the MFP and the 340B ceiling price — but not both. This non-duplication rule sounds simple in principle. In practice, there is no central mechanism to enforce it, and the operational burden falls on manufacturers.

CMS has stated explicitly that it will not assume responsibility for nonduplication of discounts between the 340B ceiling price and MFP. The Medicare Transaction Facilitator (MTF) will transmit claim-level data to manufacturers, but manufacturers must determine which claims are 340B-eligible and exclude them from MFP refund processing. If a manufacturer issues both a 340B discount and an MFP refund on the same unit of drug, the financial exposure is a double discount — with no statutory mechanism for recovery.

This article is for market access leads, government pricing teams, contract and rebate teams, and 340B compliance managers at manufacturers with MFP-selected products. It describes the non-duplication requirement, maps the data flows, identifies failure modes, and provides an operational framework for compliance.

The non-duplication requirement in the statute and guidance

What the IRA requires

Section 1192 of the Social Security Act (as added by the IRA) establishes that for 340B covered entities, the manufacturer must make the MFP available in an amount that is not duplicated with the 340B ceiling price. In plain terms:

• If the MFP is lower than the 340B ceiling price, the manufacturer provides the MFP and does not additionally provide the 340B discount.
• If the 340B ceiling price is lower than the MFP, the manufacturer provides the 340B price and the MFP does not apply.

For the first 10 negotiated Part D drugs for 2026, both scenarios exist. Some MFPs are lower than the corresponding 340B ceiling price and some are higher, depending on the product.

What CMS will and will not do

CMS's Final Guidance for Initial Price Applicability Year (IPAY) 2027 and Manufacturer Effectuation of the MFP in 2026 and 2027, published October 4, 2024, established two Medicare Transaction Facilitator modules:

• MTF Data Module (MTF-DM): Receives adjudicated Part D claims data from CMS's Drug Data Processing System (DDPS) and transmits it to manufacturers. Manufacturers use this data to identify MFP-eligible claims and calculate refunds.
• MTF Payment Module (MTF-PM): Processes refund payments from manufacturers to dispensing entities.

CMS has stated that it will not verify 340B eligibility of MFP claims. The MTF Data Module will include a "340B Claim Indicator" data element based on voluntary submission clarification codes that pharmacies may include on Part D claims, but this indicator does not represent CMS verification of 340B status. CMS is exploring the feasibility of incorporating 340B-related transactional data from covered entities or their third-party administrators in the future, but this capability does not exist for 2026.

What happened with HRSA's 340B Rebate Model Pilot

On July 31, 2025, HRSA published a notice establishing a one-year pilot program allowing manufacturers of the first 10 MFP-selected drugs to effectuate the 340B ceiling price through a rebate model rather than an upfront discount. Under the pilot, a 340B covered entity would purchase the drug at the standard acquisition cost and then submit claim data to receive a post-purchase rebate reflecting the difference between the acquisition price and the 340B ceiling price. The rebate model was designed to help manufacturers avoid the double-discount scenario: if the manufacturer could verify that a claim was already processed through the 340B rebate mechanism, it could exclude that claim from MFP refund processing.

On December 29, 2025, the U.S. District Court for the District of Maine granted a preliminary injunction halting the pilot nationwide, finding that HRSA likely violated the Administrative Procedure Act. On February 10, 2026, the court vacated and remanded the pilot program entirely in American Hospital Association et al. v. Kennedy et al., No. 25-cv-600 (D. Me.). HRSA has formally paused the program, requiring approved manufacturers to continue providing 340B pricing as upfront discounts. HRSA issued a Request for Information (RFI) on February 17, 2026, seeking input on whether a rebate model could be redesigned lawfully; the comment period closed April 20, 2026, and HRSA is reviewing responses.

As of May 2026, manufacturers must effectuate 340B pricing through the traditional upfront-discount model. The rebate pilot's vacatur increases the non-duplication challenge because manufacturers cannot use a rebate-tracking mechanism to identify which claims were already subject to 340B pricing.

The claim-level data flow for non-duplication

How MFP-eligible claims reach the manufacturer

1. A pharmacy (or other dispensing entity) dispenses a negotiated drug to a Medicare Part D beneficiary.
2. The Part D plan sponsor adjudicates the claim. Reimbursement is capped at no more than the MFP.
3. The plan sponsor submits a Prescription Drug Event (PDE) record to CMS within seven calendar days.
4. CMS transmits the PDE data to the MTF Data Module.
5. The MTF Data Module makes the claim data available to the manufacturer.
6. The manufacturer reviews the claim data, identifies MFP-eligible claims, and determines whether any are 340B-eligible.
7. For non-340B claims, the manufacturer calculates the MFP refund (the difference between what the pharmacy was reimbursed and the MFP, based on WAC as the standard default refund amount) and processes payment through the MTF Payment Module or directly to the pharmacy.
8. For 340B-eligible claims, the manufacturer excludes the claim from MFP refund processing and provides the 340B price as an upfront discount under the traditional model.

The 340B claim identification gap

The critical operational challenge is step 6: identifying which MFP-eligible claims are also 340B-eligible. The available data elements are:

The voluntary nature of the 340B claim indicators means that manufacturers cannot rely solely on the MTF data to identify 340B-eligible claims. Some 340B claims will arrive in the MTF Data Module without any 340B indicator. Some claims may carry the indicator incorrectly. Manufacturers must build a layered identification approach.

Where duplicate discounts are most likely to occur

Scenario 1: Contract pharmacy 340B claims without indicators

A 340B covered entity uses a contract pharmacy to dispense negotiated drugs to Medicare Part D beneficiaries. The contract pharmacy does not include the Submission Clarification Code "20" on the Part D claim. The claim flows through the MTF without a 340B indicator. The manufacturer processes an MFP refund on the claim. Later, the same claim is also submitted through the 340B system for replenishment or a chargeback.

Result: The manufacturer has provided both an MFP refund and a 340B discount on the same unit of drug.

Scenario 2: Multiple acquisition pathways at the same pharmacy

A pharmacy that serves both 340B and non-340B patients purchases the same drug through different wholesalers at different prices. The pharmacy inventory may be commingled. When the MTF claim data arrives, the manufacturer cannot distinguish which acquisition pathway was used for a specific dispense.

Result: The manufacturer may apply MFP refunds to claims that were already purchased at the 340B price, or withhold MFP refunds from claims that were purchased at WAC and are not 340B-eligible.

Scenario 3: Timing mismatch between MFP refund and 340B chargeback

The MFP refund process has a 14-day window from claim identification. The 340B chargeback or rebate process operates on a different timeline. A manufacturer may issue an MFP refund before the 340B chargeback for the same claim is processed, resulting in a duplicate discount that is difficult to detect retrospectively.

Scenario 4: MFP-selected drugs with 340B pricing higher than MFP

When the MFP is lower than the 340B ceiling price, the covered entity should receive the MFP rather than the 340B price. But if the covered entity's systems are still purchasing at the 340B price and submitting for MFP refunds, the manufacturer may be providing both discounts before the entity's purchasing systems are updated.

Operational framework for manufacturer non-duplication compliance

Layer 1: MTF data screening

• Enroll in the MTF Data Module as a manufacturer.
• Build an automated pipeline to ingest MTF claim data and flag claims with the 340B Claim Indicator.
• Exclude flagged claims from MFP refund processing by default.
• Route flagged claims to the 340B team for verification against internal chargeback and account data.

Layer 2: Entity-level matching

• Maintain a current map of 340B covered entities and their contract pharmacies, cross-referenced with HRSA OPAIS data.
• Match MTF claims data against known 340B dispensing relationships using NPI, pharmacy identifier, and covered entity identifier.
• Flag claims from pharmacies or entities that appear in the 340B relationship map, even if no voluntary 340B indicator was submitted.

Layer 3: Internal 340B account reconciliation

• Compare MTF refund processing records against 340B chargeback and rebate records on a monthly cycle.
• Identify any claim that received both an MFP refund and a 340B discount.
• For identified duplicates, calculate the overpayment and adjust future refund processing rules.

Layer 4: Third-party platform integration

• Evaluate third-party platforms (such as Beacon's MFP platform) that support real-time claim tracking, 340B status verification, and refund management.
• Submit the manufacturer's MFP Effectuation Plan to CMS by the required deadline, describing the non-duplication process in detail.
• Monitor CMS guidance updates for potential future integration of 340B TPA data into MTF processes.

Layer 5: Dispute resolution and exception handling

• Build a process for handling disputes from dispensing entities that believe they were incorrectly excluded from MFP refund processing (e.g., the RARC N907 code indicating a 340B claim that the pharmacy disputes).
• Establish a complaint intake system consistent with CMS's centralized complaint process, which requires complaints to be filed within 120 calendar days of the subject event.
• Track exceptions and adjust matching algorithms based on dispute outcomes.

Financial exposure modeling

For each MFP-selected product, manufacturer finance teams should model:

CMS estimates that its claims-based methodology for identifying 340B claims will make 10% to 35% of Part D claims ineligible for inflationary rebates. This range suggests significant uncertainty in 340B claim identification, which translates directly to non-duplication risk.

The aggregate exposure is large

Berkeley Research Group (BRG) estimated that more than $4 billion in duplicate discounts could be paid on selected drugs in 2026 alone. They estimate that approximately 12% of Part D dispenses for the 10 selected drugs could be subject to a duplicate discount. For a typical selected drug with an average list price of $626 per 30-day supply, a 340B discount reduces the price to approximately $238, and the net loss from a duplicate MFP refund on top of the 340B discount can exceed $300 per unit.

The pharmacy cash-flow constraint

The MFP effectuation process creates a minimum 21-day lag between dispensing and pharmacy reimbursement:

1. Pharmacy dispenses the drug and is reimbursed by the Part D plan at no more than the MFP (approximately 7 days for the plan to submit the PDE record to CMS).
2. CMS processes the PDE and transmits it to the MTF Data Module (approximately 1 day).
3. The manufacturer has 14 days from receipt of the claim data to review, determine 340B eligibility, and issue the MFP refund.

During this 21-day window, the pharmacy has purchased the drug at WAC (or a WAC-based acquisition cost) but has been reimbursed at the MFP, which can be 50% to 70% lower than WAC. For example, Jardiance's MFP is 66% lower than its current WAC. A pharmacy that dispenses 100 Jardiance prescriptions per month at WAC-minus-4% acquisition cost but is reimbursed at the MFP must float tens of thousands of dollars in receivables until the manufacturer refund arrives.

The National Community Pharmacists Association (NCPA) surveyed its members and found that a majority would not stock the first 10 Part D selected drugs, fearing they would have to dispense them at a financial loss. This creates a downstream access risk: even if the manufacturer's non-duplication system works perfectly, patients may not be able to find a pharmacy willing to dispense the drug. CMS requires manufacturers to include pharmacy cash-flow mitigation strategies in their MFP Effectuation Plans.

Worked example: pharmacy economics under MFP

Consider a drug with the following parameters:

If the claim is incorrectly identified as 340B-eligible and the refund is withheld, the pharmacy loses $26.80 on the dispense. If the claim is correctly identified as non-340B but the refund is delayed beyond 14 days, the pharmacy floats $26.80 per claim for the duration of the delay. At high dispensing volumes, this cash-flow gap becomes a balance-sheet issue.

What to monitor next

• CMS's draft guidance for IPAY 2028 and any updates to the MTF Data Module specifications that might incorporate 340B TPA data.
• HRSA's 340B Rebate Model Pilot: the pilot was vacated by the District of Maine on February 10, 2026. HRSA issued an RFI on February 17, 2026, seeking input on whether a rebate model could be redesigned. The comment period closed April 20, 2026. Monitor whether HRSA proposes a new rebate model.
• NCPDP standards evolution: adoption rates for Submission Clarification Code "20" and Submission Type Code "AA" during 2026.
• Manufacturer Effectuation Plans: CMS is making redacted plans available to dispensing entities via the MTF interface, which means competitors' non-duplication approaches may be partially visible.
• State Medicaid duplicate discount enforcement, which operates under a different statutory framework but creates parallel compliance obligations.
• Executive Order actions: the April 2025 Executive Order directing agencies to improve IRA implementation may lead to revised guidance on non-duplication.
• Manufacturer enforcement risk: if manufacturers fail to make the MFP available, CMS may impose civil monetary penalties of 10 times the difference between what was actually charged and the MFP, though CMS has stated it will give manufacturers an opportunity to justify failures and will consider MTF technical issues.

Sources

• CMS. Medicare Drug Price Negotiation Program: Final Guidance for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the MFP in 2026 and 2027. October 4, 2024. cms.gov/files/document/medicare-drug-price-negotiation-final-guidance-ipay-2027-and-manufacturer-effectuation-mfp-2026-2027.pdf
• CMS. Medicare Transaction Facilitator: Pharmacies and Other Dispensing Entities FAQ. 2025. cms.gov/files/document/pharmacy-and-dispensing-entity-mtf-faq.pdf
• USC Schaeffer Center. Operational and Policy Considerations in the Effectuation of Maximum Fair Prices in Part D. 2025. schaeffer.usc.edu/research/medicare-drug-prices-mfp-effectuation
• Avalere Health. How Will 340B Discounts Interact with Negotiated Drugs' MFP? 2024. advisory.avalerehealth.com/insights/how-will-340b-discounts-interact-with-negotiated-drugs-mfp
• Avalere Health. Updated: Key Considerations for MFP Effectuation and the 340B Rebate Model. 2025. advisory.avalerehealth.com/insights/key-considerations-for-mfp-effectuation-and-the-340b-rebate-model
• BRG (Berkeley Research Group). Implications for Duplication with the 340B Channel. October 2024.
• Johnson & Johnson. Maximum Fair Price (MFP) Implementation Plan for IPAY 2026. jnj.com/innovativemedicine/us/download/JJ%20Maximum%20Fair%20Price%20(MFP)%20Implementation%20Plan%20for%20IPAY%202026.pdf
• Drug Channels. List Price Reductions Will Deflate the Gross-to-Net Bubble. December 2025. drugchannels.net/2025/12/list-price-reductions-will-deflate.html
• 340B Report. Compliance with IRA and Associated Maximum Fair Price (MFP) Rules for 340B Covered Entities. 2025. 340breport.com/compliance-with-inflation-reduction-act-ira-and-associated-maximum-fair-price-mfp-rules-for-340b-covered-entities-sponcon-rxparadigm
• NACHC. IRA Technical Assistance Office Hour. June 2, 2025. nachc.org/wp-content/uploads/2025/10/IRA-TA-Webinar_June-2-2025_Final.pdf
• Pharmacy Times. Preparing for the Medicare Transaction Facilitator. 2025. pharmacytimes.com/view/preparing-for-the-medicare-transaction-facilitator
• American Action Forum. Maximum Fair Price Impacts in Medicare, Medicaid, and the 340B Program. americanactionforum.org/insight/maximum-fair-price-impacts-in-medicare-medicaid-and-the-340b-program
• Social Security Act § 1192, as added by the Inflation Reduction Act of 2022 (P.L. 117-169).
• HRSA. 340B Rebate Model Pilot Program. hrsa.gov/opa/340b-model-pilot-program
• American Hospital Association et al. v. Kennedy et al., No. 25-cv-600 (D. Me.), Order Granting Preliminary Injunction (Dec. 29, 2025) and Joint Motion for Vacatur and Remand (Feb. 5, 2026).